SEARCH

SEARCH BY CITATION

References

  • 1
    Van Der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 16437.
  • 2
    Chen YT, Scanlan MJ, Sahin U et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997; 94: 191418.
  • 3
    Kobayashi K, Noguchi M, Itoh K, Harada M. Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24+ prostate cancer patients. Cancer Sci 2003; 94: 6227.
  • 4
    Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 90915.
  • 5
    Hida N, Maeda Y, Katagiri K, Takasu H, Harada M, Itoh K. A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulation. Cancer Immunol Immunother 2002; 51: 21928.
  • 6
    Gohara R, Imai N, Rikimaru T et al. Phase I clinical study of cyclophilin B peptide vaccine for lung cancer patients. J Immunother 2002; 25: 43944.
  • 7
    Janeway CA, Shlomchik MJ, Travers P, Walport M. T cell receptor gene rearrangement. In: Janeway CA, Shlomchik MJ, Travers P, Walport, eds. Immunobiology, 6th edn. New York: Garland Science, 2004; 14954.
  • 8
    Mine T, Gouhara R, Hida N et al. Immunological evaluation of CTL precursor-oriented vaccines for advanced lung cancer patients. Cancer Sci 2003; 94: 54856.
  • 9
    Tsuda N, Mochizuki K, Harada M et al. Vaccination with pre-designated or evidence-based peptides for patients with recurrent gynecologic cancers. J Immunother 2004; 27: 607.
  • 10
    Yajima N, Yamanaka R, Mine T et al. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res 2005; 11: 590011.
  • 11
    Itoh K, Platsoucas CD, Balch CM. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor. J Exp Med 1988; 168: 141941.
  • 12
    Sato Y, Shomura H, Maeda Y et al. Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide. Cancer Sci 2003; 94: 8028.
  • 13
    Janeway CA, Shlomchik MJ, Travers P, Walport M. Using the immune response to attack tumors. In: Janeway CA, Shlomchik MJ, Travers P, Walport, eds. Immunobiology, 6th edn. New York: Garland Science, 2004; 63042.
  • 14
    Kitano H. Cancer robustness: tumour tactics. Nature 2003; 426: 125.
  • 15
    Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of full-length cDNA for the human MDR1 gene confers resistance to colchicines, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 1987; 84: 30048.
  • 16
    Perry CA, McTavish D. Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging 1995; 7: 4974.
  • 17
    Noguchi M, Itoh K, Suekane S et al. Immunological monitoring during combination of patient-oriented peptide vaccination and estramustin phosphate I patients with metastatic hormone refractory prostate cancer. Prostate 2004; 60: 3245.
  • 18
    Noguchi M, Itoh K, Yao A et al. Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24(+) HRPC patients. Prostate 2005; 63: 112.
  • 19
    Miyagi Y, Imai N, Sasatomi T et al. Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination of SART3 peptides. Clin Can Res 2001; 7: 395062.
  • 20
    Lewis JJ. Therapeutic cancer vaccines: using unique antigens. Proc Natl Acad Sci USA 2004; 101 (Suppl. 2): 14 653–6.
  • 21
    Yamanaka R, Homma J, Yajima N et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 2005; 11: 41607.
  • 22
    Sato Y, Maeda Y, Sasatomi T et al. A phase I trial of CTL-purecursor-oriented peptide vaccine for colorectal carcinoma patients. Br J Cancer 2004; 90: 133442.
  • 23
    Yamamoto K, Mine T, Katagiri K et al. Immunological evaluation of personalized peptide vaccination for patients with pancreatic cancer. Oncol Rep 2005; 13: 87483.
  • 24
    Tanaka S, Harada M, Mine T et al. Peptide vaccination for patients with melanoma and other types of cancers based on pre-existing peptide-specific cytotoxic T lymphocyte precursors in the periphery. J Immunother 2003; 26: 35766.
  • 25
    Noguchi M, Kobayashi K, Suetsugu N et al. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Prostate 2003; 57: 8092.
  • 26
    Noguchi M, Itoh K, Suekane S et al. Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer. Cancer Sci 2004; 95: 7784.
  • 27
    Mochizuki K, Sato Y, Tsuda N et al. Immunological evaluation of pre-designated vaccination of the peptides frequently vaccinated to cancer patients in an individualized peptide regimen. Int J Oncol 2004; 25: 12131.